Robert De Vaere joins Horizon Therapeutics
This article was originally published in Scrip
The private US biopharmaceutical company Horizon Therapeutics has named Robert De Vaere executive vice-president and chief financial officer. He most recently served as senior vice-president of finance and administration, and chief financial officer at IDM Pharma.
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.